- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Meplazumab is a humanized IgG2 monoclonal antibody that targets CD147 (basigin). It is being developed by Jiangsu Pacific Meinuoke Bio Pharmaceutical.
SARS-CoV-2 may utilise CD147 as an additional entry receptor to infect host cells . Meplazumab can block this interaction between CD147 and SARS-CoV-2 spike protein.